GIP and type 2 diabetes mellitus: Glucagon and GLP-1 receptor dual agonists and GLP-1, GIP, and glucagon receptor triple agonists have been developed, and we will be able to use them for the treatment of metabolic diseases including type 2 diabetes, in future [29].